NBSE NeuBase Therapeutics

NeuBase Therapeutics to Present at Upcoming Investor Conferences in December

NeuBase Therapeutics to Present at Upcoming Investor Conferences in December

Evercore ISI HealthCONx Conference panel discussion at 12:30 p.m. ET on December 3rd



Piper Jaffray 31st Annual Healthcare Conference presentation at 8:30 a.m. ET on December 4th

PITTSBURGH, Nov. 25, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, announced today that Dietrich Stephan, Chief Executive Officer of NeuBase, will participate in a panel discussion at the Evercore ISI HealthCONx Conference 2019, as well as present a corporate overview and business update at the 31st Annual Piper Jaffray Healthcare Conference, which are both being held in December.

Conferences Details:

Event:Evercore ISI HealthCONx Conference 2019
Panel:GenomeRx Therapeutics: The Next Exciting Wave
Date:Tuesday, Dec. 3, 2019
Time:12:30 p.m. EST
Location:Four Seasons Hotel, Boston
  
Event:31st Annual Piper Jaffray Healthcare Conference
Date:Wednesday, Dec. 4, 2019
Time:8:30 a.m. EST
Location:Lotte New York Palace, New York

About NeuBase Therapeutics

NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of genomic loci or secondary and tertiary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

NeuBase Investor Contact:

Dan Ferry

Managing Director

LifeSci Advisors, LLC

 

OP: (617) 430-7576

NeuBase Media Contact:

Travis Kruse

Russo Partners



OP: (212) 845-4272

Ned Berkowitz

Russo Partners



OP: (646) 942-5629

EN
25/11/2019

Underlying

NBSENeuBase Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NeuBase Therapeutics

 PRESS RELEASE
Free
NBSE NeuBase Therape...

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) in a timely...

April 5, 2024 1 EN
 PRESS RELEASE
Free
NBSE NeuBase Therape...

NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder

NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023. “The NeuBase Board of Directors (“Board”) appreciates input from its shareholders. The Board remains committed to completing its comprehensive exploration of strategic alternatives focused on m...

September 8, 2023 1 EN
 PRESS RELEASE
Free
NBSE NeuBase Therape...

NeuBase Therapeutics to Explore Strategic Alternatives

NeuBase Therapeutics to Explore Strategic Alternatives PITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced that its Board of Directors (the “Board”) has completed a review of the Company’s business, including the status of its programs, resources, and capabilities. The Board has made the determination to halt further development of the Company’s programs and to conduct a comprehensive exploration of strategic alte...

August 3, 2023 1 EN
 PRESS RELEASE
Free
NBSE NeuBase Therape...

NeuBase Announces Closing of $5 Million Concurrent Registered Direct O...

NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules PITTSBURGH, June 30, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced the closing of its previously announced registered direct offering for the issuance and sale of an aggregate of 578,697 of its shares of common stock (or common stock equivalents) at a purchase price...

June 30, 2023 1 EN
 PRESS RELEASE
Free
NBSE NeuBase Therape...

NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ ...

NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing New preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide Symposium First non-human primate (NHP) study to successfully redose a gene editor without an immune response Ex vivo data show Stealth Editors™ are titratable, and editing efficiency is in range for clinical benefit in various conditions Company expects to present additional data showcasing gene editing capabiliti...

June 29, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch